Geron Corporation

NASDAQ:GERN USA Biotechnology
Market Cap
$1.03 Billion
Market Cap Rank
#7881 Global
#4084 in USA
Share Price
$1.62
Change (1 day)
-1.82%
52-Week Range
$1.07 - $1.95
All Time High
$6.38
About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation (GERN) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -0.055x

Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.055x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.58 Million) by net assets ($248.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Geron Corporation - Cash Flow Conversion Efficiency Trend (1996–2024)

This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Geron Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2024)

The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $280.32 Million $-218.62 Million -0.780x -15.28%
2023-12-31 $247.95 Million $-167.74 Million -0.677x +57.51%
2022-12-31 $80.00 Million $-127.38 Million -1.592x -110.65%
2021-12-31 $126.42 Million $-95.56 Million -0.756x -139.23%
2020-12-31 $210.95 Million $-66.65 Million -0.316x +2.57%
2019-12-31 $135.16 Million $-43.83 Million -0.324x -174.34%
2018-12-31 $177.73 Million $-21.01 Million -0.118x +40.31%
2017-12-31 $103.80 Million $-20.56 Million -0.198x -31.94%
2016-12-31 $122.38 Million $-18.37 Million -0.150x +11.83%
2015-12-31 $142.13 Million $-24.20 Million -0.170x -338.00%
2014-12-31 $130.71 Million $9.35 Million 0.072x +111.65%
2013-12-31 $59.76 Million $-36.68 Million -0.614x +4.66%
2012-12-31 $85.65 Million $-55.15 Million -0.644x -51.28%
2011-12-31 $146.60 Million $-62.39 Million -0.426x -85.19%
2010-12-31 $192.74 Million $-44.29 Million -0.230x +8.56%
2009-12-31 $172.58 Million $-43.37 Million -0.251x -0.84%
2008-12-31 $168.46 Million $-41.98 Million -0.249x -92.48%
2007-12-31 $205.67 Million $-26.63 Million -0.129x +14.63%
2006-12-31 $173.92 Million $-26.38 Million -0.152x -40.32%
2005-12-31 $190.71 Million $-20.61 Million -0.108x +49.11%
2004-12-31 $122.06 Million $-25.93 Million -0.212x +7.43%
2003-12-31 $106.32 Million $-24.40 Million -0.229x +78.23%
2002-12-31 $29.74 Million $-31.34 Million -1.054x -189.24%
2001-12-31 $61.54 Million $-22.42 Million -0.364x -71.18%
2000-12-31 $63.92 Million $-13.61 Million -0.213x +58.99%
1999-12-31 $26.20 Million $-13.60 Million -0.519x -118.28%
1998-12-31 $32.80 Million $-7.80 Million -0.238x +36.49%
1997-12-31 $21.10 Million $-7.90 Million -0.374x +10.75%
1996-12-31 $23.60 Million $-9.90 Million -0.419x --